The Experts below are selected from a list of 33 Experts worldwide ranked by ideXlab platform
Christian Nather - One of the best experts on this subject based on the ideXlab platform.
-
crystal structures and properties of two new pseudopolymorphic modifications of the glucocorticoide Triamcinolone Diacetate
Solid State Sciences, 2006Co-Authors: Viktor Suitchmezian, Inke Jes, Christian NatherAbstract:Abstract Two new solvates of Triamcinolone Diacetate were found in addition, to those reported previously. The acetonitrile solvate (form E) crystallizes monoclinic in space group P21, whereas the methylene chloride solvate (form F) crystallizes orthorhombic in space group P212121. In all forms the Triamcinolone Diacetate molecules are linked by intermolecular hydrogen bonding. From this arrangement channels are formed in which the solvent molecules are embedded. Both forms were investigated by differential thermoanalysis and thermogravimetry. On heating, for each form a mass loss is observed, which is accompanied with endothermic events in the DTA curve. Mass spectroscopic investigations clearly shows that in this step the solvent molecules are emitted. In these measurements one cannot differ between desolvation and melting. If the residues formed after the first TG steps are investigated by X-ray powder diffraction, only amorphous samples are obtained. If the solvents are removed at room temperature under normal pressure or in vacuum the commercial available form of Triamcinolone Diacetate is obtained which is also used in therapy. If the acetonitrile solvate is tempered at 80 °C for several days significant changes in the powder pattern are observed, which may indicate the formation of a new polymorphic form.
-
investigations on the polymorphism and pseudopolymorphism of Triamcinolone Diacetate
International Journal of Pharmaceutics, 2006Co-Authors: Viktor Suitchmezian, Inke Jes, Christian NatherAbstract:Abstract The glucocorticoide Triamcinolone Diacetate was investigated for polymorphism. Crystallization experiments in different solvents performed at room-temperature reveal that in most cases solvates has formed (form B) which are isotypic and which crystallize in the orthorhombic space group P 2 1 2 1 2 1 . In their crystal structure channels are formed in which the solvent molecules are located. In some other solvents the commercial available form A is the thermodynamic most stable form. On heating form A using differential scanning calorimetry (DSC) the compound melts at a peak temperature of 136 °C without any further polymorphic transformation. If the solvents are removed at higher temperatures using simultaneous differential thermoanalysis and thermogravimetry coupled to mass spectroscopy (DTA–TG–MS) the remaining residues are amorphous against X-rays because the compound melts directly after desolvation. If the desolvation process is investigated by DSC measurements the same is observed for most solvents but in some cases different peaks for desolvation and melting are observed. In this case a new modification can be isolated after removing the solvent (form C). If the solvent are removed in vacuum or by storage at room-temperature always the commercial available form A is obtained, whereas desolvation experiments at 80 °C indicate the formation of a further polymorphic modification (form D).
-
Triamcinolone Diacetate chloro form solvate
Acta Crystallographica Section E-structure Reports Online, 2006Co-Authors: Viktor Suitchmezian, Inke Jess, Christian NatherAbstract:In the crystal structure of the title compound, 16α,21-diacetoxy-9α-fluoro-11β,17α-dihydroxy-1,4-pregnadiene-3,20-dione chloroform solvate, C25H31FO8·CHCl3, the molecules are connected via O—H⋯O hydrogen bonding. Channels, in which the chloroform molecules are located, are formed in the direction of the crystallographic a axis.
B Mukerji - One of the best experts on this subject based on the ideXlab platform.
-
thu0214 effect of Triamcinolone Diacetate injections in early dupuytren s contracture and stenosing tenosynovitis of the hand
Annals of the Rheumatic Diseases, 2001Co-Authors: B MukerjiAbstract:Background Dupuytren’s contracture and other fibrosing conditions of the hand are generally progressive, causing limitation of function and decreasing grip strength. Long term results of surgical procedures are less than optimal with high recurrence and extension rates. Other non-operative therapies such as slow skeletal traction, radiation, splinting, ultrasound and enzymatic fasciotomy have not proven to be clinically useful. Objectives The objective of this study was to determine the effectiveness of steroid injections in slowing the progression of fibrosis and contractures in early Dupuytren’s disease and conditions causing stenosing tenosynovitis of the hand. Methods Twenty-three patients were studied. There were 12 men and 11 women with an age range of 35 to 72 years. Of these patients four also had diabetes mellitus and three had rheumatoid arthritis. Eighteen patients had Dupuytrens’ contracture. Fifteen had bilateral contractures and three in one hand only. None of them had contractures in the proximal interphalangeal joints. One had mild flexion contracture at the second, third and fourth metacarpophalangeal joints. Two had bilateral De Quervain’s tenosynovitis and three had isolated fibrous nodules in one flexor tendon in the hand. All patients received one or two Triamcinolone Diacetate injections in the fibrous nodules, cords and tendon sheaths. Additionally, five patients received oral non-steroidal antiinflammatory agents for one to two weeks. Patients with Dupuytren’s contracture demonstrated softening of the symptomatic chords, improvement of grip strength and partial resolution of nodules. The other patients had complete resolution of their condition. Results Patients were followed for one to seven years and maintained their functional improvement. No patient’s contracture progressed or required surgery or radiotherapy. There were no complications such as hematoma, skin necrosis, infection, granuloma formation, decrease in grip strength, transient paresthesia or flexion deformity of the fingers. Conclusion In conclusion, early Dupuytren’s disease and other fibrosing tenosynovitis of the hands can be safely and effectively treated with injections of Triamcinolone Diacetate and this appears to prevent progression of these conditions.
Viktor Suitchmezian - One of the best experts on this subject based on the ideXlab platform.
-
crystal structures and properties of two new pseudopolymorphic modifications of the glucocorticoide Triamcinolone Diacetate
Solid State Sciences, 2006Co-Authors: Viktor Suitchmezian, Inke Jes, Christian NatherAbstract:Abstract Two new solvates of Triamcinolone Diacetate were found in addition, to those reported previously. The acetonitrile solvate (form E) crystallizes monoclinic in space group P21, whereas the methylene chloride solvate (form F) crystallizes orthorhombic in space group P212121. In all forms the Triamcinolone Diacetate molecules are linked by intermolecular hydrogen bonding. From this arrangement channels are formed in which the solvent molecules are embedded. Both forms were investigated by differential thermoanalysis and thermogravimetry. On heating, for each form a mass loss is observed, which is accompanied with endothermic events in the DTA curve. Mass spectroscopic investigations clearly shows that in this step the solvent molecules are emitted. In these measurements one cannot differ between desolvation and melting. If the residues formed after the first TG steps are investigated by X-ray powder diffraction, only amorphous samples are obtained. If the solvents are removed at room temperature under normal pressure or in vacuum the commercial available form of Triamcinolone Diacetate is obtained which is also used in therapy. If the acetonitrile solvate is tempered at 80 °C for several days significant changes in the powder pattern are observed, which may indicate the formation of a new polymorphic form.
-
investigations on the polymorphism and pseudopolymorphism of Triamcinolone Diacetate
International Journal of Pharmaceutics, 2006Co-Authors: Viktor Suitchmezian, Inke Jes, Christian NatherAbstract:Abstract The glucocorticoide Triamcinolone Diacetate was investigated for polymorphism. Crystallization experiments in different solvents performed at room-temperature reveal that in most cases solvates has formed (form B) which are isotypic and which crystallize in the orthorhombic space group P 2 1 2 1 2 1 . In their crystal structure channels are formed in which the solvent molecules are located. In some other solvents the commercial available form A is the thermodynamic most stable form. On heating form A using differential scanning calorimetry (DSC) the compound melts at a peak temperature of 136 °C without any further polymorphic transformation. If the solvents are removed at higher temperatures using simultaneous differential thermoanalysis and thermogravimetry coupled to mass spectroscopy (DTA–TG–MS) the remaining residues are amorphous against X-rays because the compound melts directly after desolvation. If the desolvation process is investigated by DSC measurements the same is observed for most solvents but in some cases different peaks for desolvation and melting are observed. In this case a new modification can be isolated after removing the solvent (form C). If the solvent are removed in vacuum or by storage at room-temperature always the commercial available form A is obtained, whereas desolvation experiments at 80 °C indicate the formation of a further polymorphic modification (form D).
-
Triamcinolone Diacetate chloro form solvate
Acta Crystallographica Section E-structure Reports Online, 2006Co-Authors: Viktor Suitchmezian, Inke Jess, Christian NatherAbstract:In the crystal structure of the title compound, 16α,21-diacetoxy-9α-fluoro-11β,17α-dihydroxy-1,4-pregnadiene-3,20-dione chloroform solvate, C25H31FO8·CHCl3, the molecules are connected via O—H⋯O hydrogen bonding. Channels, in which the chloroform molecules are located, are formed in the direction of the crystallographic a axis.
Jack Zuckner - One of the best experts on this subject based on the ideXlab platform.
-
TREATMENT OF RHEUMATOID ARTHRITIS BY INTRAMUSCULAR Triamcinolone ACETONIDE AND Triamcinolone Diacetate BY
2016Co-Authors: Jack ZucknerAbstract:The results of a study (Zuckner, 1961) evaluating the therapeutic response of intra-articularly ad-ministered Triamcinolone acetonide * (hereafter refer-red to as TActn) and Triamcinolone Diacetate* (TDac) suggested that large doses of these hormones had a profound systemic effect. The injection of either of these hormones in a dose of 100 mg. into a knee joint affected by rheumatoid arthritis resulted in a generalized anti-inflammatory response, includ-ing improvement in other inflamed joints as well as that injected. This generalized improvement usually persisted for 2 to 3 weeks. These favourable findings led to further study with these steroids, utilizing the more practical intramuscular route of administration. Procedure The acetonide and Diacetate derivatives ofTriamcinolone were injected intramuscularly into 36 patients with rheumatoid arthritis. There were 112 injections, 68 of TActn and 44 of TDac. The dose per injection was 100 mg. These steroids were compared with hydro-cortisone acetate (FAc) given by intramuscular injection in the same patients; there were seven injections of the 100 mg. dose of FAc, and eleven of 500 mg. Patients were examined once a week at first in most instances, less often later. Subjective improvement in pain and stiffness and objective evidence of tenderness, heat, swelling, range of motion, capsular thickening, and fluid in involved articulations were determined and an estimated composite percentage recorded. These signs and symptoms were evaluated at each visit. The interval between injections was usually determined by the patient's subjective response, particularly the mani-festation of pain. An effort was made to maintain a
Inke Jes - One of the best experts on this subject based on the ideXlab platform.
-
crystal structures and properties of two new pseudopolymorphic modifications of the glucocorticoide Triamcinolone Diacetate
Solid State Sciences, 2006Co-Authors: Viktor Suitchmezian, Inke Jes, Christian NatherAbstract:Abstract Two new solvates of Triamcinolone Diacetate were found in addition, to those reported previously. The acetonitrile solvate (form E) crystallizes monoclinic in space group P21, whereas the methylene chloride solvate (form F) crystallizes orthorhombic in space group P212121. In all forms the Triamcinolone Diacetate molecules are linked by intermolecular hydrogen bonding. From this arrangement channels are formed in which the solvent molecules are embedded. Both forms were investigated by differential thermoanalysis and thermogravimetry. On heating, for each form a mass loss is observed, which is accompanied with endothermic events in the DTA curve. Mass spectroscopic investigations clearly shows that in this step the solvent molecules are emitted. In these measurements one cannot differ between desolvation and melting. If the residues formed after the first TG steps are investigated by X-ray powder diffraction, only amorphous samples are obtained. If the solvents are removed at room temperature under normal pressure or in vacuum the commercial available form of Triamcinolone Diacetate is obtained which is also used in therapy. If the acetonitrile solvate is tempered at 80 °C for several days significant changes in the powder pattern are observed, which may indicate the formation of a new polymorphic form.
-
investigations on the polymorphism and pseudopolymorphism of Triamcinolone Diacetate
International Journal of Pharmaceutics, 2006Co-Authors: Viktor Suitchmezian, Inke Jes, Christian NatherAbstract:Abstract The glucocorticoide Triamcinolone Diacetate was investigated for polymorphism. Crystallization experiments in different solvents performed at room-temperature reveal that in most cases solvates has formed (form B) which are isotypic and which crystallize in the orthorhombic space group P 2 1 2 1 2 1 . In their crystal structure channels are formed in which the solvent molecules are located. In some other solvents the commercial available form A is the thermodynamic most stable form. On heating form A using differential scanning calorimetry (DSC) the compound melts at a peak temperature of 136 °C without any further polymorphic transformation. If the solvents are removed at higher temperatures using simultaneous differential thermoanalysis and thermogravimetry coupled to mass spectroscopy (DTA–TG–MS) the remaining residues are amorphous against X-rays because the compound melts directly after desolvation. If the desolvation process is investigated by DSC measurements the same is observed for most solvents but in some cases different peaks for desolvation and melting are observed. In this case a new modification can be isolated after removing the solvent (form C). If the solvent are removed in vacuum or by storage at room-temperature always the commercial available form A is obtained, whereas desolvation experiments at 80 °C indicate the formation of a further polymorphic modification (form D).
